FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC CancerNetwork
2026
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC Targeted Oncology
FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food
The U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader…